CVRx to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 15, 2022

Rhea-AI Summary

CVRx, a commercial-stage medical device company, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. The company will hold a conference call at 5:30 p.m. Eastern Time to discuss the results. Investors can join by dialling (833) 730-3980 for U.S. callers or +1 (720) 405-2140 internationally, referencing conference code 2879175. The FDA-approved Barostim™ device is designed to improve heart failure symptoms by stimulating the body's baroreceptors.

Positive

• Barostim™ received FDA Breakthrough Device designation.
• Barostim™ is FDA-approved for heart failure patients in the U.S.
• Barostim™ also has CE Mark approval for heart failure and resistant hypertension in the European Economic Area.

Negative

• None.

MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2021 financial and operating results after market close on Tuesday, February 15, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

To listen to the conference call on your telephone, please dial (833) 730-3980 for U.S. callers, or +1 (720) 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 2879175. To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations. The webcast replay will be available on the CVRx website for 12 months following completion of the call.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:

Lisa Murray
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
lisa@trevicomm.com

FAQ

When will CVRx release its Q4 and full year 2021 financial results?

CVRx plans to release its financial results on February 15, 2022, after market close.

What time is the CVRx conference call for financial results?

The conference call will be held at 5:30 p.m. Eastern Time on February 15, 2022.

How can I listen to the CVRx conference call?

You can listen by calling (833) 730-3980 for U.S. callers or +1 (720) 405-2140 for international callers, referencing conference code 2879175.

What is Barostim and its significance?

Barostim is an FDA-approved device for improving symptoms in heart failure patients, utilizing neuromodulation to activate the body's baroreflex.

Does Barostim have any regulatory approvals?

Yes, Barostim has the FDA Breakthrough Device designation and CE Mark approval for heart failure and resistant hypertension.